Get started
mitchdevan

BLRX

Long
BioLineRx Ltd. (NASDAQ:BLRX)  
mitchdevan  
NASDAQ:BLRX   BioLineRx Ltd.
0
0
BLRX Biotech
• Stem cell treatment for leukemia
• $75 million market cap, $16 million in cash
• Several products in pipeline offering potential catalysts
• $3.00 - $4.00 Upside
• $1.60 Downside
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.